| Name | Title | Contact Details |
|---|
At VMG Health, were more than just a team of experts; were trusted partners in the business of healthcare. Backed by a team of over 300 professionals and a history of more than 70,000 engagements since 1995, we bring experience deep and wide to every project. Our national client base ranges from large health systems to small practices and everything in between, including investors and private equity firms. Our solutions-oriented approach to client needs is bolstered by our strong market position, extensive contacts, unparalleled tools and solutions, and expert insights. We are proud to serve as the single source for all our clients valuation, strategic, and compliance needs. At VMG Health, we make healthcare business performance personal.
Safe & Green Holdings Corp., a leading modular solutions company, operates under core capabilities which include the development, design, and fabrication of modular structures, meeting the demand for safe and green solutions across various industries. The firm supports third party and in-house developers, architects, builders and owners in achieving faster execution, greener construction, and buildings of higher value. SGH Corp. products have been featured in several media outlets including Fortune, NY Times, NY Post, USA Today, CNN, Washington Post and more. The company has completed projects for: US Army and Navy, US Department of Veteran Affairs, The City of Santa Monica, Port of Houston Authority, Aman Resorts, BareBurger, Equinox, HGTV, Lacoste, Marriott Hotels & Resorts, Mini Cooper, Starbucks and more.
Handcrafted outdoor furniture with over 20 years of DEDON experience. As a manufacturer of exclusive outdoor furniture, DEDON is one of the worlds leading providers in this industry and has received numerous international design awards. The company, which was founded in 1990 by the former professional soccer player Bobby Dekeyser, revolutionized the outdoor furniture market with its groundbreaking designs within only a few years. The basis for DEDONs success is a highly durable synthetic fiber manufactured at the headquarters in the North of Germany. Developed over 20 years ago, the unique DEDON fiber still is considered "the original" in the industry; the "Made by DEDON" seal stands for the highest standards of quality and design. DEDON furniture is designed by international designers, matches German quality standards in terms of production, and is manufactured by hand in a traditional fashion by braiding artisans on the island of Cebu in the Philippines. Every piece of DEDON furniture embodies the combination of modern technology and century-old craftsmanship.
In a time when humanity needs to rethink the future to sustain life on this planet, we consider responsible business a necessary game changer. That is why we are a company that offers 100% organic cotton products for customers who seek delicious, sustainable goods of premium quality. We want our products to last long enough to be passed on. We create them to be enjoyed and used. And we insist on developing a new, sustainable standard of designed goods. #design #functionality #longlasting #newstandard #BCorp #GOTS #organic #feelgood
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.